CRP and infection: Of the 2 of 16 patients (12.5%) who had previously “suspended” rilonacept for off-treatment observation at the 18-month decision milestone, 1 investigator-assessed pericarditis recurrence (without C-reactive protein elevation) occurred in the peri-COVID-19 period (18 days after infection), approximately 4.5 months after rilonacept cessation.